Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Is immunosuppressive therapy the anchor treatment to achieve remission in systemic sclerosis?

Cappelli S, Bellando-Randone S, Guiducci S, Matucci-Cerinic M.

Rheumatology (Oxford). 2014 Jun;53(6):975-87. Review.

PMID:
24185765
2.

Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): efficacy of maintenance immunosuppression in responders and non-responders.

Iudici M, Cuomo G, Vettori S, Bocchino M, Sanduzzi Zamparelli A, Cappabianca S, Valentini G.

Semin Arthritis Rheum. 2015 Feb;44(4):437-44. doi: 10.1016/j.semarthrit.2014.09.003. Epub 2014 Sep 8.

PMID:
25282395
3.

Cyclophosphamide versus mycophenolate mofetil in scleroderma interstitial lung disease (SSc-ILD) as induction therapy: a single-centre, retrospective analysis.

Shenoy PD, Bavaliya M, Sashidharan S, Nalianda K, Sreenath S.

Arthritis Res Ther. 2016 Jun 2;18(1):123. doi: 10.1186/s13075-016-1015-0.

4.

Interstitial lung disease in systemic sclerosis.

Bussone G, Mouthon L.

Autoimmun Rev. 2011 Mar;10(5):248-55. doi: 10.1016/j.autrev.2010.09.012. Epub 2010 Sep 21. Review.

PMID:
20863911
5.

[Current treatment of systemic sclerosis. Part I. Immunosuppressive treatment].

Sicińska J, Rudnicka L.

Pol Merkur Lekarski. 2008 Aug;25(146):192-5. Review. Polish.

PMID:
18942346
6.

Disease-modifying treatment in systemic sclerosis: current status.

Quillinan NP, Denton CP.

Curr Opin Rheumatol. 2009 Nov;21(6):636-41. doi: 10.1097/BOR.0b013e3283310d57. Review.

PMID:
19726995
7.

Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis.

Lee YH, Woo JH, Choi SJ, Ji JD, Song GG.

Lupus. 2010 May;19(6):703-10. doi: 10.1177/0961203309357763. Epub 2010 Jan 11. Review.

PMID:
20064907
8.

Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials.

Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H.

Nephrol Dial Transplant. 2007 Jul;22(7):1933-42. Epub 2007 Apr 3. Review.

PMID:
17405792
9.

Immunosuppressive therapies for the induction treatment of proliferative lupus nephritis: a systematic review and network metaanalysis.

Tian SY, Feldman BM, Beyene J, Brown PE, Uleryk EM, Silverman ED.

J Rheumatol. 2014 Oct;41(10):1998-2007. doi: 10.3899/jrheum.140050. Epub 2014 Sep 15. Review.

PMID:
25225281
10.

Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.

Yilmaz N, Can M, Kocakaya D, Karakurt S, Yavuz S.

Int J Rheum Dis. 2014 Nov;17(8):923-8. doi: 10.1111/1756-185X.12399. Epub 2014 May 26.

PMID:
24864029
11.

Oral cyclophosphamide for active scleroderma lung disease: a decision analysis.

Khanna D, Furst DE, Clements PJ, Tashkin DP, Eckman MH.

Med Decis Making. 2008 Nov-Dec;28(6):926-37. doi: 10.1177/0272989X08317015. Epub 2008 Apr 28.

PMID:
18443209
12.
13.

Interstitial lung disease in systemic sclerosis: where do we stand?

Cappelli S, Bellando Randone S, Camiciottoli G, De Paulis A, Guiducci S, Matucci-Cerinic M.

Eur Respir Rev. 2015 Sep;24(137):411-9. doi: 10.1183/16000617.00002915. Review.

14.

Brief Report: long-term outcome of a randomized clinical trial comparing methotrexate to cyclophosphamide for remission induction in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

Faurschou M, Westman K, Rasmussen N, de Groot K, Flossmann O, Höglund P, Jayne DR; European Vasculitis Study Group.

Arthritis Rheum. 2012 Oct;64(10):3472-7. doi: 10.1002/art.34547.

15.

[Auto-immune hepatitis: therapeutic management].

Pariente A.

Gastroenterol Clin Biol. 2003 May;27(5 Suppl):B13-9. Review. French. No abstract available.

16.

Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?

Iudici M, Moroncini G, Cipriani P, Giacomelli R, Gabrielli A, Valentini G.

Autoimmun Rev. 2015 Jul;14(7):575-8. doi: 10.1016/j.autrev.2015.02.002. Epub 2015 Feb 21. Review.

PMID:
25709096
17.

Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study.

Moroni G, Raffiotta F, Trezzi B, Giglio E, Mezzina N, Del Papa N, Meroni P, Messa P, Sinico AR.

Rheumatology (Oxford). 2014 Sep;53(9):1570-7. doi: 10.1093/rheumatology/ket462. Epub 2014 Feb 6.

PMID:
24505125
18.

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR.

Arthritis Rheum. 2005 Aug;52(8):2461-9.

19.

Is mycophenolate mofetil an effective alternative in azathioprine-intolerant patients with chronic active Crohn's disease?

Miehsler W, Reinisch W, Moser G, Gangl A, Vogelsang H.

Am J Gastroenterol. 2001 Mar;96(3):782-7.

PMID:
11280551
20.

Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?

Bérezné A, Valeyre D, Ranque B, Guillevin L, Mouthon L.

Ann N Y Acad Sci. 2007 Sep;1110:271-84.

PMID:
17911442

Supplemental Content

Support Center